Sep. 16 at 2:40 PM
$CDTX @billsmall, you figure this pattern is a buyer looking to get in at a better price? Or shorts trying to cover without losing their shirts ahead of some upside event risk?
At this point, it seems pretty clear that a fall 2025 phase 3 start is good to go (trial listed in clinicaltrials.gov, evidence of recruiting). A few other items are still out there that could be confirmed imminently:
* FDA Breakthrough Therapy designation
* FDA recognizing phase 2b as pivotal
* FDA Commissioner's National Priority Voucher
* BARDA submission outcome (government year end is September 30)
The FDA items could conceivably all come at the same time, and BARDA pretty much any time from now to end of year.
I personally wouldn't want to be short through this. The only downside risk that I could possibly see in the short term is that some safety signal popped up since the phase 2b readout, but the late breaking presentation in Singapore seems to make that a very unlikely possibility.
Short
$CDTX = bad idea, IMHO.
